Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Huangdai tablets for advanced primary liver cancer (phase II)
ChiCTR2100050191Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Compound Huangdai Tablet in hepatocellular carcinoma (HCC), sponsored by Changhai Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
Compound Huangdai Tablet
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100050191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050191.